Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein
AssigneeBoehringer Ingelheim International GmbH
InventorsPhilipp MUELLER, Klaus ERB, Patrik ERLMANN, Guido WOLLMANN
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CD80 extracellular domain Fc-fusion protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.
Claims14
A method for the treatment of solid cancers comprising the administration of a pharmaceutical composition to a patient in need thereof, wherein said pharmaceutical composition comprises a recombinant vesicular stomatitis virus encoding in its genome at least one CD80 extracellular domain Fc-fusion protein, wherein the CD80 extracellular domain Fc-fusion protein comprises the extracellular domain of CD80 and the Fc domain of an IgG wherein the CD80 extracellular domain Fc-fusion protein comprises SEQ ID NO:4;
- and the gene coding for the wild-type glycoprotein G of the recombinant vesicular stomatitis virus is replaced by the gene coding for the glycoprotein G (GP) of Lymphocyte choriomeningitis virus (LCMV), and/or the wild-type glycoprotein G is replaced by the glycoprotein G (GP) of LCMV.
Dependencies are inferred from the claim text.